SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE TO
(Rule 14d-100)
TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
OCATA
THERAPEUTICS, INC.
(Name of Subject Company (Issuer))
Laurel Acquisition Inc.
an indirect wholly-owned subsidiary of
Astellas Pharma Inc.
(Names of Filing Persons (Offerors))
Common Stock, $0.001 par value per share
(Title of Class of Securities)
67457L100
(CUSIP Number
of Class of Securities (Underlying Common Stock))
Yoshihiko Hatanaka
President and Chief Executive Officer
Astellas Pharma Inc.
2-5-1, Nihonbashi-Honcho, Chuo-ku
Tokyo 103-8411, Japan
+(81)-3-3244-3000
(Name,
Address, and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Person)
Copies to:
Scott F. Smith, Esq.
Jack S. Bodner, Esq.
Covington & Burling LLP
The New York Times Building
620 Eighth Avenue
New
York, NY 10018-1045
(212) 841-1000
Calculation
of Filing Fee
|
|
|
Transaction Valuation* |
|
Amount of Filing Fee** |
N/A
|
|
N/A |
|
* |
Pursuant to General Instruction D to Schedule TO, a filing fee is not required in connection with this filing as it relates solely to preliminary communications made before the commencement of a tender offer.
|
¨ |
Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or
the Form or Schedule and the date of its filing. |
|
|
|
Amount Previously Paid: |
|
Filing Party: |
Form or Registration No. |
|
Date Filed: |
x |
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
Check the appropriate boxes below to designate any transactions to which the statement relates:
|
x |
third-party tender offer subject to Rule 14d-1. |
|
¨ |
issuer tender offer subject to Rule 13e-4. |
|
¨ |
going-private transaction subject to Rule 13e-3. |
|
¨ |
amendment to Schedule 13D under Rule 13d-2. |
Check the following box if the filing is a final
amendment reporting the results of the tender offer: ¨
This filing relates solely to preliminary communications made before the commencement of a tender offer for the
outstanding common stock of Ocata Therapuetics, Inc. (Ocata) by Laurel Acquisition Inc. (the Purchaser), an indirect wholly-owned subsidiary of Astellas Pharma Inc. (Astellas) to be commenced
pursuant to the Agreement and Plan of Merger, dated as of November 10, 2015, by and among Astellas, Purchaser and Ocata.
The following documents
related to the proposed tender offer are attached as exhibits to this communication:
|
|
|
English translation of Press Release of Astellas Pharma Inc. filed with the Tokyo Stock Exchange and dated November 10, 2015; |
|
|
|
Joint Press Release of Ocata Therapeutics, Inc. and Astellas Pharma Inc., dated November 10, 2015; and |
|
|
|
English Translation of Investor Presentation of Astellas Pharma Inc., dated November 10, 2015. |
Important Additional Information
The tender offer for
the outstanding common stock of Ocata has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Ocata common stock, nor is it a substitute for
the tender offer materials that Astellas and its acquisition subsidiary will file with the SEC upon commencement of the tender offer. At the time the tender offer is commenced, Astellas will file a tender offer statement on Schedule TO with the SEC,
and Ocata will file a solicitation/recommendation statement on Schedule 14D-9 with respect to the offer. THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND OTHER OFFER DOCUMENTS) AND THE
SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY AND CONSIDERED BY OCATAS STOCKHOLDERS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Both the tender offer statement and the
solicitation/recommendation statement will be mailed to Ocatas stockholders free of charge. A free copy of the tender offer statement and the solicitation/recommendation statement will also be made available to all stockholders of Ocata by
contacting Ocata at info@ocata.com or by phone at (508) 756-1212. In addition, the tender offer statement and the solicitation/recommendation statement (and all other documents filed with the SEC) will be available at no charge on the
SECs website: www.sec.gov, upon filing with the SEC.
Exhibit Index
|
|
|
Exhibit
No. |
|
Description |
|
|
99.1 |
|
English translation of Press Release of Astellas Pharma Inc. filed with the Tokyo Stock Exchange and dated November 10, 2015. |
|
|
99.2 |
|
Joint Press Release of Ocata Therapeutics, Inc. and Astellas Pharma Inc., dated November 10, 2015. |
|
|
99.3 |
|
English Translation of Investor Presentation of Astellas Pharma Inc., dated November 10, 2015. |
|
|
|
[English Translation of Japanese Press Release] |
|
Exhibit 99.1 |
On November 10, 2015
Company Name: Astellas Pharma Inc.
Representative: Representative Director, President & CEO Yoshihiko Hatanaka
TSE Ticker: 4503
(URL:http://www.astellas.com/jp)
TSE
First Section
Fiscal Year End: March
Contact: Vice President, Corporate Communications Masaaki Usui
Tel: +81-3-3244-3201
Astellas
Entered into a Definitive Agreement to Acquire
Ocata Therapeutics and Plans Commencement of a Tender Offer
- New Step Forward in Ophthalmology with Cell Therapy Approach -
Astellas Pharma Inc. (Headquarters: Tokyo, Representative Director, President and CEO: Yoshihiko Hatanaka, Astellas) and Ocata
Therapeutics, Inc. (NASDAQ:OCATA, Headquarters: Massachusetts in the United States, President and CEO: Paul Wotton, Ocata), a biotechnology company in the United States, announced that today (Japan time) they have entered into a
definitive agreement (the Agreement) under which Astellas will acquire Ocata.
The board of directors of Astellas has approved today
that pursuant to the Agreement Laurel Acquisition Inc. (Laurel), a wholly-owned subsidiary of Astellas US Holding Inc. (Headquarters: Illinois in the United States), will commence a tender offer for Ocata shares in cash (the
Tender Offer).
Under the Agreement, Laurel aims to acquire all outstanding shares of common stock of Ocata, for a price of US$8.50 per
share in cash. The offer price represents a premium of 79% to Ocatas closing share price of US$4.75 on November 6, 2015. The all-cash transaction is valued at approximately US$379 million (total amount to purchase all outstanding common
shares, options, warrants and other securities). The Tender Offer and the subsequent acquisition via the merger (the Acquisition) will be conducted in exchange for cash and are not conditioned on financing. The board of directors
of Ocata has resolved to recommend that Ocatas stockholders tender into the Tender Offer.
1. |
Objectives of the Acquisition and the Tender Offer, etc. |
(1) |
Objectives of the Acquisition and the Tender Offer |
Astellas is striving to create solid and
resilient continuity of growth over the mid- to long-term through the pursuit of three main strategies Maximizing the Product Value, Creating Innovation, Pursuing Operational Excellence in Astellas
Strategic Plan 2015-2017 (Strategic Plan). Particularly in pursuit
of Creating Innovation, we are exploring new opportunities in addition to
strengthening our capabilities to create innovative medicines. Weve selected ophthalmology as one of new prioritized therapeutic areas for research besides muscle diseases and are promoting drug discovery research. Were also proactively
investing on regenerative medicine, especially cell therapy and next-generation vaccine as a part of initiatives to new technologies and modalities.
Ocata is a clinical stage biotechnology company focusing on the research and development of cell therapy in the field of ophthalmology. Ocata
has strength in the fundamental technology that can establish differentiated cells from pluripotent stem cells and in the clinical development of cell therapy. Ocatas most advanced retinal pigment epithelium (RPE) cell programs for the
treatment of dry age-related macular degeneration and Stargardts macular degeneration are in clinical stage. Moreover, several cell therapy programs centering around ophthalmology are in research and pre-clinical stages.
The acquisition of Ocata is an important initiative for Astellas to achieve the goals of the Strategic Plan. Achieving the creation of
innovative drugs via cell therapy will contribute to addressing the unmet medical needs of patients suffering from severe ophthalmic diseases. The strategic rationale of the Acquisition is as follows.
|
|
|
Establish a presence in ophthalmology |
|
|
|
Establish a leading position in cell therapy by obtaining Ocatas world-class capabilities |
We highly value Ocatas R&D capabilities, including its world-leading researchers in cell therapy, commented Yoshihiko
Hatanaka, Representative Director, President and CEO, Astellas. Were confident that we will turn innovative science into value for patients through the creation of new value by combining both companies capabilities under One
Astellas, where Ocata will be taking a key role in Astellas R&D in ophthalmology and cell therapy.
Paul Wotton,
Ph.D., President and CEO, Ocata said, I am impressed by the vision and commitment of Astellas and believe that with their global resources behind our regenerative platform, patients suffering from debilitating diseases like AMD and SMD will
soon benefit from having access to regenerative medicine.
(2) |
Matters concerning material agreements between Laurel and the Ocatas shareholders concerning tender into the Tender Offer |
Ocatas shareholders including Ocatas directors and officers (in the aggregate, approximately 1.7% of total common shares
outstanding) have agreed to tender the shares of common stock of Ocata that they hold into the Tender Offer.
(3) |
Matters concerning the two-step acquisition |
After the Tender Offer, Laurel will be merged with
and into Ocata, and Ocata, as the surviving company, is expected to become Astellas consolidated subsidiary.
2
2. |
Overview of the Tender Offer |
(1) |
Tender Offer Period (Plan) |
The Tender Offer period will commence no later than
November 25, 2015 and expire 20 business days after its commencement.
Possibility of the extension of the Tender Offer period by
Ocatas request:
If the Tender Offer conditions are not satisfied, Laurel may be required to extend the Tender Offer under certain
circumstances; however, in no event will it be obligated to extend the Tender Offer period beyond May 9, 2016.
(2) |
Type of Stock that is to be Acquired |
Common Stock
US $8.50 (8 Dollars and 50 Cents) per share of Common Stock
Note: Tender Offer Price has been determined through the negotiation with Ocata, considering projected earnings, the value of pipelines,
potential market opportunities, the value of its technology, etc. and advised by the third party professional.
(4) |
Capital Required for the Acquisition |
Approximately $379 million
This amount is the sum of the acquisition of total common shares outstanding, outstanding options, outstanding warrants and other securities.
Astellas has enough cash to consummate the Acquisition and the Acquisition is not conditioned on financing.
(5) |
Conditions of Tender Offer |
The Tender Offer is subject to customary closing conditions,
including regulatory approvals and the tender of a majority of Ocatas shares of common stock on a fully diluted basis.
3. |
Minimum number of shares tendered |
Laurel will consummate the Tender Offer in the event
that a majority of Ocatas shares of common stock on a fully diluted basis is tendered.
4. |
Change in the number of shares of Ocata common stock that we own as a result of the Tender Offer |
Percentage owned prior to the Tender Offer: 0%
3
Percentage owned after the Tender Offer: 100% (*)
* |
This number is based on the situation where we are able to acquire 100% of Ocatas Common Stock via the Tender Offer and subsequent merger. |
|
|
|
|
|
|
|
① Company name |
|
Ocata Therapeutics, Inc. |
|
|
② Address |
|
33 Locke Drive, Marlborough, MA 01752, US |
|
|
③ Representatives title and name |
|
President and CEO: Paul Wotton |
|
|
④ Business |
|
Research and development of new therapies for ophthalmic diseases in the field of regenerative medicine |
|
|
⑤ Capital(Stockholders equity) |
|
US $13,761,005 (as of September 30, 2015) |
|
|
⑥ Date of establishment |
|
Founded in 1994, changed its name to current one in 2014 |
|
|
⑦ Number of shares outstanding |
|
42,300,462 shares of Common Stock (as of October 30, 2015) |
|
⑧ Relationship between Ocata and Astellas |
|
|
|
|
|
Capital Relationship: |
|
There is no capital relationship between Astellas and Ocata required to be disclosed. |
|
|
|
|
|
Personnel Relationship: |
|
There is no personnel relationship between Astellas and Ocata required to be disclosed. |
|
|
|
|
|
Business Relationship: |
|
There is no business relationship between Astellas and Ocata required to be disclosed. |
|
|
|
|
|
Applicable Relationships with Related Parties: |
|
Ocata is not affiliated parties of Astellas. |
|
⑨ Financial results in recent fiscal years |
(THOUSANDS OF US DOLLARS)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal Year ended December 2012 |
|
|
Fiscal Year ended December 2013 |
|
|
Fiscal Year ended December 2014 |
|
Sales |
|
|
466 |
|
|
|
225 |
|
|
|
158 |
|
Net income |
|
|
(34,584 |
) |
|
|
(31,022 |
) |
|
|
(34,749 |
) |
Total assets |
|
|
8,497 |
|
|
|
3,908 |
|
|
|
5,737 |
|
Net assets |
|
|
(23,144 |
) |
|
|
(22,534 |
) |
|
|
(2,736 |
) |
** |
Cited from Form 10-K which Ocata submitted to the U.S. Securities and Exchange Commision (SEC). |
The Tender Offer and consummation of the Acquisition are expected to
have a minor impact on Astellas financial results for the fiscal year ending March 31, 2016.
4
7. |
Financial Advisors and Legal Counsels |
Citigroup Inc. is acting as exclusive financial
advisor to Astellas and Covington & Burling LLP is acting as legal counsel.
Jefferies LLC is acting as exclusive financial
advisor to Ocata and Goodwin Procter LLP is acting as legal counsel.
A detailed schedule of the Tender Offer will be announced on the SECs website
(http://www.sec.gov).
Cautionary Statement Regarding Forward-Looking Statements
Any statements made in this communication that are not statements of historical fact, including statements about the expected timetable for completing the
transaction and Astellas and Ocatas beliefs and expectations and statements about Astellas proposed acquisition of Ocata, including the timing of and closing conditions to the acquisition, and the potential effects of the
acquisition on both Astellas and Ocata are forward-looking statements that are based on managements beliefs, certain assumptions and current expectations and should be evaluated as such. These statements may be identified by their use of
forward-looking terminology such as the words expects, projects, anticipates, intends and other similar words. Forward-looking statements include statements that may relate to Astellas or
Ocatas plans, objectives, strategies, goals, future events, future revenues or performance, and other information that is not historical information. Such forward-looking statements involve risks and uncertainties that could cause actual
results to differ materially from those projected. These risks and uncertainties include, but are not limited to, general economic, business and market conditions and the satisfaction of the conditions to closing of the proposed transaction. For a
more complete discussion of certain of the risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements with respect to Ocata, see the discussion of risks and uncertainties in Ocatas
annual report on Form 10-K for the fiscal year ended December 31, 2014, its most recent Quarterly Report on Form 10-Q, and other SEC filings. The forward-looking statements contained in this news release are made as of the date hereof, and
neither Astellas nor Ocata undertakes any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise, except as required by law.
Important Additional Information
The tender offer for
the outstanding common stock of Ocata has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Ocata common stock, nor is it a substitute for
the tender offer materials that Astellas and its acquisition subsidiary will file with the SEC upon commencement of the tender offer. At the time the tender offer is commenced, Astellas will file a tender offer statement on Schedule TO with the SEC,
and Ocata will file a solicitation/recommendation statement on Schedule 14D-9 with respect to the offer. THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND OTHER OFFER DOCUMENTS) AND THE
SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY AND CONSIDERED BY OCATAS STOCKHOLDERS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Both the tender offer statement and the
solicitation/recommendation statement will be mailed to Ocatas stockholders free of charge. A free copy of the tender offer statement and the solicitation/recommendation statement will also be made available to all stockholders of Ocata by
contacting Ocata at info@ocata.com or by phone at (508) 756-1212. In addition, the tender offer statement and the solicitation/recommendation statement (and all other documents filed with the SEC) will be available at no charge on the
SECs website: www.sec.gov, upon filing with the SEC.
5
OCATAS STOCKHOLDERS ARE ADVISED TO READ THE SCHEDULE TO AND THE SCHEDULE 14D-9, AS EACH MAY BE AMENDED OR
SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED
TRANSACTION AND THE PARTIES THERETO.
6
Exhibit 99.2
Astellas to Acquire Ocata Therapeutics
- New Step Forward in Ophthalmology with Cell Therapy Approach -
Tokyo and Massachusetts, November 10, 2015Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka,
Astellas) and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO: Paul Wotton, Ocata), a biotechnology company focused on the research and development of new therapies in the field of regenerative
medicine, primarily cell therapy addressing unmet medical needs in ophthalmology patients, announced today that they have entered into a definitive agreement. Under the agreement, Astellas will acquire Ocata through Laurel Acquisition Inc., a
wholly-owned subsidiary of Astellas US Holding, Inc. (Laurel). The boards of directors of both Astellas and Ocata have unanimously approved the agreement.
Pursuant to the agreement, Laurel will commence a tender offer for all outstanding shares of common stock of Ocata, for a price of US$8.50 per share in cash
(the Tender Offer). Promptly upon successful completion of the Tender Offer, Laurel will be merged into Ocata, and any remaining shares of common stock of Ocata will be canceled and converted into the right to receive the offer
price (except for shares held by stockholders who properly demand appraisal rights under Delaware law). The board of directors of Ocata has resolved to recommend that Ocatas stockholders tender into the Tender Offer.
Each of the directors and executive officers of Ocata entered into support agreements with Astellas and Laurel, pursuant to which such directors and officers,
among other things, agreed to tender the shares of common stock of Ocata that they hold into the Tender Offer. Shares held by these directors and officers represent, in the aggregate, approximately 1.7% of the share of common stock of Ocata
outstanding on this date.
The acquisition of Ocata represents the coming together of two companies with significant accomplishments and a shared
commitment to development innovative therapies that address the unmet medical needs of patients suffering from severe ophthalmic diseases. The acquisition also represents a step toward achieving Astellas Strategic Plan 2015-2017.
Further, acquiring Ocata will enable Astellas to establish a presence in ophthalmology and a leading position in
cell therapy.
We highly value Ocatas R&D capabilities, including its world-leading researchers in cell therapy, commented Yoshihiko
Hatanaka, President and CEO, Astellas. Were confident that we will turn innovative science into value for patients through the creation of new value by combining both companies capabilities under One Astellas, where
Ocata will be taking a key role in Astellas R&D in ophthalmology and cell therapy.
Paul Wotton, Ph.D., President and CEO, Ocata said,
I am impressed by the vision and commitment of Astellas and believe that with their global resources behind our regenerative platform, patients suffering from debilitating diseases like AMD and SMD will soon benefit from having access to
regenerative medicine.
Financial Details and Closing Conditions
Consummation of the transaction is subject to customary closing conditions, including antitrust approvals and the tender of a majority of Ocatas shares
of common stock on a fully diluted basis. The offer price represents a premium of 79% to Ocatas closing share price of US$4.75 on November 6, 2015. The all-cash transaction is valued at approximately US$379 million including the purchase
of all common shares, options, warrants and other securities. The Tender Offer period is expected to commence no later than November 25, 2015, and will expire 20 business days after its commencement, unless otherwise extended. If the Tender
Offer conditions are not satisfied, Astellas may be required to extend the Tender Offer under certain circumstances; however, in no event will Astellas be obligated to extend the Tender Offer beyond May 9, 2016.
The Tender Offer and consummation of the acquisition is expected to have a minor impact on Astellas financial results for the fiscal year ending
March 31, 2016.
Citigroup Inc. is acting as exclusive financial advisor to Astellas and Covington & Burling LLP is acting as legal counsel.
Jefferies LLC is acting as exclusive financial advisor to Ocata and Goodwin Procter LLP is acting as legal counsel.
2
About Astellas
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and
reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are
also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please
visit our website at www.astellas.com/en.
About Ocata
Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of new therapies in the field of
regenerative medicine. Ocatas most advanced products are in clinical trials for the treatment of Stargardts macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocatas intellectual property
portfolio includes pluripotent stem cell platforms hESC and induced pluripotent stem cell (iPSC) and other cell therapy research programs. For more information on Ocata, please visit www.ocata.com.
Cautionary Statement Regarding Forward-Looking Statements
Any statements made in this communication that are not statements of historical fact, including statements about the expected timetable for completing the
transaction and Astellas and Ocatas beliefs and expectations and statements about Astellas proposed acquisition of Ocata, including the timing of and closing conditions to the acquisition, and the potential effects of the
acquisition on both Astellas and Ocata are forward-looking statements that are based on managements beliefs, certain assumptions and current expectations and should be evaluated as such. These statements may be identified by their use of
forward-looking terminology such as the words expects, projects, anticipates, intends and other similar words. Forward-looking statements include statements that may relate to Astellas or
Ocatas plans, objectives, strategies, goals, future events, future revenues or performance, and other information that is not historical information. Such forward-looking statements involve risks and uncertainties that could cause actual
results to differ materially from those projected. These risks and uncertainties include, but are not limited to, general economic, business and market conditions and the satisfaction of the conditions to closing of the proposed transaction. For a
more complete discussion of certain of the risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements with respect to Ocata, see the discussion of risks and uncertainties in Ocatas
annual report on Form 10-K
3
for the fiscal year ended December 31, 2014, its most recent Quarterly Report on Form 10-Q, and other SEC filings. The forward-looking statements contained in this news release are made as
of the date hereof, and neither Astellas nor Ocata undertakes any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise, except as required by law.
Important Additional Information
The tender offer for
the outstanding common stock of Ocata has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Ocata common stock, nor is it a substitute for
the tender offer materials that Astellas and its acquisition subsidiary will file with the SEC upon commencement of the tender offer. At the time the tender offer is commenced, Astellas will file a tender offer statement on Schedule TO with the SEC,
and Ocata will file a solicitation/recommendation statement on Schedule 14D-9 with respect to the offer. THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND OTHER OFFER DOCUMENTS) AND THE
SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY AND CONSIDERED BY OCATAS STOCKHOLDERS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Both the tender offer statement and the
solicitation/recommendation statement will be mailed to Ocatas stockholders free of charge. A free copy of the tender offer statement and the solicitation/recommendation statement will also be made available to all stockholders of Ocata by
contacting Ocata at info@ocata.com or by phone at (508) 756-1212. In addition, the tender offer statement and the solicitation/recommendation statement (and all other documents filed with the SEC) will be available at no charge on the
SECs website: www.sec.gov, upon filing with the SEC.
OCATAS STOCKHOLDERS ARE ADVISED TO READ THE SCHEDULE TO AND THE SCHEDULE 14D-9, AS EACH
MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT
THE PROPOSED TRANSACTION AND THE PARTIES THERETO.
Contacts:
Astellas Pharma Inc.
Corporate Communications
TEL: 03-3244-3201 FAX: 03-5201-7473
http://www.astellas.com/en
4
U.S Media Contact
Marjorie Moeling
TEL: 224-205-5205 MOBILE: 847-682-7471
Marjorie.moeling@astellas.com
Ocata Therapeutics, Inc.
Investors:
Westwicke Partners
John Woolford, 443-213-0506
john.woolford@westwicke.com
or
Press:
Russo Partners
David Schull, 858-717-2310
david.schull@russopartnersllc.com
###
5
Exhibit 99.3
Ocata Therapeutics, Inc. (NASDAQ:OCAT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocata Therapeutics, Inc. (NASDAQ:OCAT)
Historical Stock Chart
From Apr 2023 to Apr 2024